RET and melanoma: In the metallothionein (MT)/ret transgenic model, the human ret transgene is driven by the mouse MT promoter-enhancer, which activates MAPK signaling and promotes the development of spontaneous melanomas; a subset of these mice develop metastases of the brain and other distal sites [112,113].